Health Care Provider Videos

Health Care Provider Videos

Learn more about INLYTA® (axitinib) in combination with pembrolizumab from health care providers

DR THOMAS HUTSON—OVERVIEW OF KEYNOTE-426 TRIAL RESULTS

Dr Thomas Hutson, an oncologist with Texas Oncology at Baylor University Medical Center and Professor of Medicine at Texas A&M College of Medicine, discusses the results of the KEYNOTE-426 trial of INLYTA + pembrolizumab vs sunitinib for the first-line treatment of patients with advanced RCC.

MEGAN PRICE, NURSE PRACTITIONER—THERAPY MANAGEMENT STRATEGIES

Megan Price, a nurse practitioner with Texas Oncology at Baylor University Medical Center, discusses therapy management strategies for patients being treated with INLYTA in combination with pembrolizumab as a first-line treatment for advanced RCC.

BAVENCIO is a registered trademark of Merck KGaA, Darmstadt, Germany. All other trademarks are property of their respective owners.